Gene-expression profiles for the 235-patient DLBCL cohort of Rosenwald et al. (2002), used as the high-dimensional benchmark in the encrypted distributed Cox-lasso demonstration.
Format
A numeric matrix with 235 rows (patients) and 6416
columns (Lymphochip microarray features). Row names are the
patient LYM identifiers, matching DLBCL$ID; column names are
the microarray UNIQIDs. Values are log-ratios on the original
scale.
Source
Rosenwald A, Wright G, Chan WC, et al. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine 346(25):1937–1947. Data: https://llmpp.ccr.cancer.gov/DLBCL/.
Details
Derived from the public Lymphoma/Leukemia Molecular Profiling
Project release (https://llmpp.ccr.cancer.gov/DLBCL/; files
DLBCL_patient_data_NEW.txt and NEJM_Web_Fig1data). Patients
are matched to expression columns by LYM number. Of the 7399
Lymphochip features, the 6416 observed in at least 75% of the 240
patients are retained, and their remaining missing values are imputed
by the per-feature mean (Bayle, Fan and Lou, 2025, impute by the median); the
five patients with zero follow-up time are excluded, leaving 235
patients. Standardization is deliberately not baked into the
stored matrix — it is performed inside the encrypted pipeline
so that the demonstration exercises encrypted standardization.
The full processing script is data-raw/DLBCL.R.